National Resource for Translational and Developmental Proteomics

摘要 翻译和发育蛋白质组学国家资源，或NRTDP，提出了一系列 在其第二阶段运作中的活动。在2015年启动并在每个项目中建立功能计划 P41 BTRR的使命，我们现在转向拟议的2020-2025年授权期，以制定新的 技术，并通过使从业者能够分析蛋白质形式和许多合作者来翻译它们 以更深入地了解它们的生物学。与P41计划的变化一致，我们主要强调 使蛋白质组学的基础和临床研究成为可能，将创新延伸到早期 自上而下蛋白质组学新实现的采用者，对许多人来说，这本身就是一个新概念 相遇。我们还接受各种机制，包括企业伙伴关系、社区参与、培训 和传播，以确保即使在P41国家资源日落之后也能产生可持续的影响。 在启动我们的运营之后，我们现在提出了三个新的技术研发项目，六个 新的推动生物医学项目、高度动态的协作项目集和一系列社区 参与活动，以继续在目前支持的一组P41资源中发挥我们的独特作用 由NIGMS提供。我们的资源提供的技术和支持将继续为合作者提供 正交数据流，并进一步证明了更精确地测量蛋白质的价值 与当代的“自下而上”的蛋白质组学技术。从心脏病到癌症研究， 神经学和与年龄相关的疾病免疫学，蛋白质和蛋白形态及其后遗症的分析 翻译修饰将继续揭示潜在的分子机制，通过新的和细胞特异性的 精密蛋白质组学技术。这将使临床医生和细胞生物学家能够跨越四种主要疾病 领域，并以一种国际公认的新风格卓越显著地支持美国的利益 基于质谱学的蛋白质组学，补充了全国现有的投资领域。这个 合作者和培训活动的地理分布与成熟的资源保持一致 达到2015年原赠款提案中设想的业务水平。 西北大学既有基础科学方面的环境，又有很强的制度支持 以及位于大芝加哥地区的医学研究园区。利用一支专业的蛋白质学家团队 NRTDP拥有不同的背景和经验，事实证明，它是一家能力很强的企业， 大力支持NIGMS获得的方案支持。作为一个单位，我们高度重视对 精神和P41计划的文字，并寻求与当前投资组合中的其他P41协同 得到了NIGMS和NIH的支持。

Abstract The National Resource for Translational and Developmental Proteomics, or NRTDP, proposes a constellation of activities in its second phase of operation. After launching in 2015 and establishing functional programs in each mission of a P41 BTRR, we now turn toward the proposed granting period from 2020 – 2025 to develop new technologies and translate them by enabling both practitioners to analyze proteoforms and many collaborators to understand their biology more deeply. Consistent with changes in the P41 program, we place major emphasis on enabling basic and clinical research in proteomics, reduction to practice to extend innovations to early adopters of new implementations of top-down proteomics, which is itself a new concept to many we encounter. We also embrace mechanisms including corporate partnerships, community engagement, training and dissemination to ensure a sustainable impact even after the sunset of this P41 National Resource. After booting up our operation, we now posit three new Technology Research and Development Projects, six new Driving Biomedical Projects, a highly dynamic set of collaborative projects and an array of Community Engagement activities to continue serving our unique role within the set of P41 Resources currently supported by NIGMS. The technology and support emanating from our resource will continue to provide collaborators with orthogonal data streams and further demonstrate the value of measuring proteins more precisely than is possible with current-generation technology of “bottom-up” proteomics. From heart disease to cancer research, neurology and age-related disorders to immunology, the analysis of proteins and proteoforms and their post- translational modifications will continue to unveil underlying molecular mechanisms through new and cell-specific technologies for precision proteomics. This will enable clinicians and cell biologists across four major disease areas, and significantly bolster American interests with an internationally-recognized excellence in a new style of mass spectrometry-based proteomics that complements existing areas of investment across the nation. The geographical distribution of collaborators and training activities are consistent with a mature resource that reaches the level of operation envisaged in the original grant proposal in 2015. The institutional support is very strong from an environment of Northwestern University on both its basic science and medical research campuses in the greater Chicago area. Leveraging a team of professional proteomicists with diverse backgrounds and experiences, the NRTDP has proven to be a highly capable enterprise that returns strongly on programmatic support received by NIGMS. As a unit, we place high value on attentiveness to the spirit and the letter of the P41 program, and also seek to synergize with other P41s within the current portfolio supported by the NIGMS and NIH.